Market Cap: $1.68B
SI
Stoke Therapeutics, Inc.
STOK
NASDAQ (NASDAQ Global Select)USD
Market Cap: $1.68B
Stoke Therapeutics: Pioneering RNA Medicine for Genetic Disorders Stoke Therapeutics, Inc., a biotechnology company based in Bedford, Massachusetts, is at the forefront of RNA medicine, focusing on re…
Stoke Therapeutics Advances RNA Medicine with Innovative Technology Stoke Therapeutics, Inc., a biotechnology company based in Bedford, Massachusetts, focuses on pioneering RNA medicine to restore pro…
Revolutionizing Dravet Syndrome Treatment: Stoke Therapeutics' Promising Data on Zorevunersen Stoke Therapeutics, Inc., a pioneering biotechnology firm specializing in RNA medicine, presents groundbre…
GeneDx Launches Patient Access Program to Enhance Genetic Testing for Pediatric Epilepsy In a significant development within the biopharmaceutical industry, GeneDx, a leader in genomic insights, launc…
Stoke Therapeutics Advances Treatment for Dravet Syndrome with Breakthrough Therapy Designation Stoke Therapeutics, Inc., a biotechnology company specializing in RNA medicine, is making significant st…
Zorevunersen Receives Breakthrough Therapy Designation for Dravet Syndrome: A Milestone for Stoke Therapeutics Stoke Therapeutics, Inc. announces a significant development in its quest to address Drav…
Stoke Therapeutics Advances Epilepsy Treatment Research at AES 2024 Stoke Therapeutics, Inc., a pioneering biotechnology company specializing in RNA medicine, is set to showcase its latest research at…
Stoke Therapeutics Showcases Breakthrough Data on Zorevunersen at AES 2024 Annual Meeting Stoke Therapeutics, Inc., a pioneering biotechnology firm in RNA medicine, prepares to unveil groundbreaking d…